普拉洛芬联合玻璃酸钠治疗干眼疗效评价的Meta分析

目的：运用Meta分析方法系统评价近年来普拉洛芬联合玻璃酸钠治疗干眼的疗效。

方法：按Cochrane系统评价方法,计算机检索Medline、EMbase、Cochrane图书馆、万方数据库、维普数据库、中国知网数据库,纳入2014-01-01/2018-06-01普拉洛芬联合玻璃酸钠治疗干眼的随机对照研究,使用RevMan5.3统计软件进行资料提取与Meta分析。

结果：共纳入8个随机对照研究,全部为中文文献,合计1 008例患者。Meta分析结果显示,与单纯使用玻璃酸钠对比,普拉洛分联合玻璃酸钠对患者BUT、SⅠt、FL、干眼症状及总体疗效有明显改善作用,差异具有统计学意义(P<0.05)。

结论：普拉洛芬联合玻璃酸钠治疗干眼的疗效优于单纯使用玻璃酸钠。     

Clinical Evaluation of Pranoprofen Combined with Fluorometholone Eye Drops on Postoperative Reaction of Corneal Cross-linking

 Purpose: To evaluate the efficacy and safety of pranoprofen eye drops for reducing postoperative ocular pain and inflammation after corneal cross-linking (CXL). Methods: Twenty-seven patients (38 eyes) with keratoconus undergoing CXL were examined and randomly divided into control (12 cases; 18 eyes) and experimental groups (15 cases; 20 eyes). The patients in the control group were given fluorometholone eye drops, and those in the experimental group were administered with fluorometholone combined with pranoprofen eye drops．Corneal irritation and haze were compared between the two groups at 1 month postoperatively． Results: At 1 to 3 days after surgery,the corneal irritation in the experimental group was significantly reduced compared with that in the control group (P＜0.05), but there was no significant difference on 5 to 7 days postoperatively (P＞0.05)．The average degree of haze in the experimental group was significantly lower than that in the control group 1 month after surgery (P＜0.05), but there was no significant difference in the best-corrected vision acuity and intraocular pressure between the two groups. There were 2 cases with >20 mmHg intraocular pressure in the control group. Conclusion: The combined use of fluorometholone and pranoprofen can significantly reduce inflammatory response,alleviate corneal irritation at early stage after CXL,effectively prevent and control the average of haze,and reduce the incidence of steroid-induced ocular hypertension after surgery．     

普拉洛芬滴眼液联合小牛血去蛋白提取物滴眼液治疗中重度干眼

目的：探究普拉洛芬滴眼液联合小牛血去蛋白提取物滴眼液治疗中重度干眼的临床效果。

方法：选取2016-01/2017-01在郑州市第二人民医院接受治疗的中重度干眼患者84例132眼。按随机数字表法分为对照组42例68眼,观察组42例64眼,其中对照组采用聚乙烯醇滴眼液联合普拉洛芬滴眼液治疗,观察组采用普拉洛芬滴眼液联合小牛血去蛋白提取物滴眼液治疗。在治疗前及治疗后记录患者主客观评分。

结果：治疗前两组患者FL、BUT、SⅠt、视力4个客观指标组间比较差异无统计学意义(P>0.05)。两组患者治疗后干眼症状评分均较治疗前显著下降,组内比较差异有统计学意义(P<0.05); 治疗后观察组较对照组干眼症状评分均显著下降,差异有统计学意义(P<0.05)。两组治疗后FL评分治疗前显著下降、BUT、SⅠt、视力指标较治疗前显著上升,组内比较差异有统计学意义(P<0.05); 治疗后,各指标组间比较差异有统计学意义(P<0.05),说明观察组受试者治疗后客观症状改善优于对照组。所有患者均未出现严重不良反应,安全性较好。

结论：普拉洛芬滴眼液联合小牛血去蛋白提取物滴眼液治疗中重度干眼的临床效果较好,且安全性有保证。     

Dose dependent cytotoxicity of pranoprofen in cultured human corneal endothelial cells by inducing apoptosis

Pranoprofen (PPF), a non-steroidal anti-inflammatory drugs (NSAIDs), is often used in keratitis treatment in clinic. Several studies have assessed in vitro the cytotoxicity of topical NSAIDs to corneal epithelial cells due to its importance for predicting human corneal toxicity. Damage by cytotoxic drugs can result in excessive loss of human corneal endothelial (HCE) cells which lead to decompensation of the endothelium and eventual loss of visual acuity. However, the endothelial cytotoxicity of PPF has not yet been reported using an in vitro model of HCE cells. This study assessed the cytotoxicity of PPF to HCE cells and its underlying mechanism. Cellular viability was determined using inverted phase contrast light microscopy, and plasma membrane permeability, genomic DNA fragmentation, and ultrastructure were detected by acridine orange/ethidium bromide staining, DNA agarose gel electrophoresis, and transmission electron microscopy (TEM), respectively. The results on cellular viability showed that PPF at concentrations ranging from 0.0625 to 1.0?g/l had poignant cytotoxicity to HCE cells, and the extent of its cytotoxicity was dose- and time-dependent. Further characterization indicated that PPF induced plasma membrane permeability elevation, DNA fragmentation, and apoptotic body formation, proving its apoptosis inducing effect on HCE cells. In conclusion, PPF above 0.0625?g/l has poignant cytotoxicity on HCE cells in vitro by inducing cell apoptosis, and should be carefully employed in eye clinic.     

人工泪液联合普拉洛芬治疗青光眼术后干眼症的疗效

目的:观察人工泪液联合普拉洛芬滴眼液治疗小梁切除术后合并轻中度干眼症的临床疗效。方法:前瞻性研究。对我院2013-11/2014-06就诊的小梁切除术后合并干眼症的病例63例63眼,按就诊顺序,随机分为观察组和对照组,观察组采用人工泪液联合普拉洛芬点眼治疗,对照组采用人工泪液治疗。分别于治疗前、治疗后1,2,4wk,对症状、体征进行评分,并观察泪膜破裂时间(BUT)、泪液分泌试验(SⅠt)、荧光素染色(FL),比较每组治疗前、后效果差异。结果:用药第2wk后,观察组感觉性症状好转,评分差异有统计学意义(P<0.05),两组的角膜荧光染色评分差异均有统计学意义(P<0.05);4wk后,两组感觉性症状及观察组眼表体征均有好转,评分差异有统计学意义(P<0.05),观察组的泪膜破裂时间及两组的角膜荧光素染色评分差异均有统计学意义(P<0.05)。结论:人工泪液联合普拉洛芬滴眼液治疗小梁切除术后合并轻中度干眼症效果良好。     

依碳酸氯替泼诺与双氯芬酸钠滴眼液对季节性过敏性结膜炎疗效比较

目的 比较依碳酸氯替泼诺滴眼液和双氯芬酸钠滴眼液治疗季节性过敏性结膜炎的有效性和安全性。 方法 季节性过敏性结膜炎病人44例,随机分为依碳酸氯替泼诺滴眼液组（A组）和双氯芬酸钠滴眼液组（B组）,A、B组分别采用依碳酸氯替泼诺与双氯芬酸钠滴眼液每天点眼4次。根据用药后临床症状和体征进行疗效评价;并对治疗过程中所有不良事件进行记录。结果 治疗14 d后,A组结膜改变和眼部瘙痒程度改变的有效率为95.2%,B组为69.6%,两组有效率比较差异有显著性（χ2=4.86,P〈0.05）;A组畏光和分泌物消失占76.1%,B组占21.7%,两组比较差异有显著性（χ2=13.05,P〈0.01）。两组药物相关不良事件的发生情况比较差异无显著性（P〉0.05）。结论 依碳酸氯替泼诺滴眼液能明显缓解季节性过敏性结膜炎病人的临床症状, 治疗效果优于双氯芬酸钠滴眼液, 其安全性与双氯芬酸钠滴眼液类似。     

普拉洛芬滴眼液控制准分子激光上皮角膜磨镶术后反应的临床评价

目的 :评价普拉洛芬滴眼液 (pranoprofen)控制LASEK(准分子激光上皮角膜磨镶术 ,laserepithelialker atomileusis)术后疼痛及炎症反应的疗效和安全性。方法 :采用随机对照试验 ,试验组滴用普拉洛芬滴眼液 ,每日 3次 ,加氟美瞳滴眼液 ,每日 4次 ,对照组单滴用氟美瞳滴眼液 ,每日4次。观察两组患者畏光、流泪、异物感、疼痛以及裂隙灯观察的情况 ,每项指标均按由轻到重分为无 (0分 )、轻 (1分 )、中 (2分 )、重 (3分 )和极重 (4分 )五级 ,各项指标得分相加后得到综合评分 ,比较两组在术前、术后 1d、术后 4d、术后 7d及术后 14d的综合评分差异。结果 :共 6 2例 115眼完成试验 ,平均年龄为 (2 6 .4 6± 6 .5 6 )岁。平均屈光度为 (- 5 .75±2 .2 5 )D。试验组和对照组术后综合评分在术后第 1天分别为 5 .84± 2 .81和 8.84± 2 .4 1(P <0 .0 0 1) ,第 4天分别为 0 .90± 1.12和 4 .6 7± 2 .5 1(P <0 .0 0 1) ,差别均有显著性。第 7天分别为 0 .10± 0 .31和 0 .16± 0 .37(P =0 .39) ,第 14天分别为0 .0 34± 0 .19和 0 .0 2± 0 .13(P =0 .5 7) ,差别均无显著性。症状消失的天数分别为 (2 .4 1± 0 .6 3)d和 (3.84± 0 .75 )d(P <0 .0 0 1) ,差别有显著性。试验组未见严重并发症和副作用。结论 :普拉洛芬     

普拉洛芬滴眼液不同用药时间对干眼症疗效的影响

目的　探讨普拉洛芬滴眼液不同用药时间对干眼症疗效的影响。方法　选取我院眼科门诊诊断为双眼干眼症的患者１１７例,按照随机数字表法将患者分成普拉洛芬１４ｄ组（３９例）、普拉洛芬３０ｄ组（４０例）和对照组（３８例）。普拉洛芬１４ｄ组给予１ｇ·Ｌ－１普拉洛芬滴眼液（１４ｄ）联合１ｇ·Ｌ－１玻璃酸钠滴眼液（３０ｄ）;普拉洛芬３０ｄ组给予１ｇ·Ｌ－１普拉洛芬滴眼液（３０ｄ）联合１ｇ·Ｌ－１玻璃酸钠滴眼液（３０ｄ）,对照组仅给予１ｇ·Ｌ－１玻璃酸钠滴眼液（３０ｄ）。给药方法均为局部滴双眼,每次１滴,每天４次。分别于治疗前后检测３组患者的泪液分泌试验Ｉ（ＳｃｈｉｒｍｅｒＩｔｅｓｔ,ＳＩｔ）、泪膜破裂时间（ｔｅａｒｂｒｅａｋ-ｕｐｔｉｍｅ,ＢＵＴ）和角膜荧光素染色（ｃｏｒｎｅａｌｆｌｕｏｒｅｓｃｅｎｔｓｔａｉｎｉｎｇ,ＦＬ）评分。结果　治疗前３组患者人口基线特征比较差异均无统计学意义（均为Ｐ＞０．０５）。治疗后普拉洛芬１４ｄ组ＳＩｔ（７．１１±１．３６）ｍｍ和ＢＵＴ（８．４２±０．７９）ｓ均高于对照组ＳＩｔ（５．１９±０．８５）ｍｍ和ＢＵＴ（５．９２±１．２４）ｓ;ＦＬ评分（０．７３±０．７２）显著低于对照组（１．８８±０．７１）,差异均有统计学意义（ｔＳＩｔ＝８．０００,Ｐ＜０．００１;ｔＢＵＴ ＝１０．８７０,Ｐ＜０．００１;ｔＦＬ＝－７．６６７,Ｐ＜０．００１）;治疗后普拉洛芬３０ｄ组ＳＩｔ（７．３８±１．０１）ｍｍ和ＢＵＴ（８．１２±１．００）ｓ均高于对照组,ＦＬ评分（０．８８±０．６８）显著低于对照组,差异均有统计学意义（ｔＳＩｔ＝９．１２５,Ｐ＜０．００１;ｔＢＵＴ＝９．５６５,Ｐ＜０．００１;ｔＦＬ ＝－６．６６７,Ｐ＜０．００１）;但治疗后普拉洛芬１４ｄ组与普拉洛芬３０ｄ组的ＳＩｔ、ＢＵＴ和ＦＬ评分差异均无统计学意义（ｔＳＩｔ＝－１．１２５,０．４＞Ｐ＞０．２;ｔＢＵＴ＝１．３０４,０．２＞Ｐ＞０．１;ｔＦＬ＝－１．０００,０．４＞Ｐ＞０．２）。结论　短期应用１ｇ·Ｌ－１普拉洛芬滴眼液治疗干眼症即可达到较好的疗效,它是辅助治疗干眼症的有效药物。     

短期应用普拉洛芬滴眼液治疗老年干眼症的疗效及安全性

目的：探讨短期应用普拉洛芬滴眼液治疗老年干眼症的疗效及安全性。

方法：将2016-06/2017-05于我院接受治疗的100例老年干眼症患者随机均分为两组,每组各50例,均双侧发病,取右眼为观察眼。观察组50眼应用1g/L普拉洛芬滴眼液联合1g/L玻璃酸钠滴眼液治疗; 对照组50眼应用1g/L玻璃酸钠滴眼液治疗。分别于用药前、用药2wk时,进行泪液分泌试验Ⅰ(Schirmer Ⅰ),检测眼表疾病指数(OSDI)、泪膜破裂时间(BUT)、眼表染色(OSS)评分、球结膜上皮细胞中人类白细胞DR抗原(HLA-DR)、CD11b表达水平,同时观察不良反应与并发症情况。

结果：两组治疗前Schirmer Ⅰ实验结果、OSDI、BUT、OSS、HLA-DR及CD11b表达均接近,差异无统计学意义(P>0.05); 经治疗后OSDI、OSS、CD11b均明显下降,BUT均明显上升,组内差异有统计学意义(P<0.01); 治疗后观察组OSDI、OSS、HLA-DR明显低于对照组,BUT明显高于对照组,差异有统计学意义(P<0.05)。HLA-DR表达与OSDI、OSS呈正相关,与BUT呈负相关。两组均未见明显不良反应及并发症。

结论：短期应用普拉洛芬能够有效提升老年干眼症疗效,改善患者临床症状,且普拉洛芬治疗机制可能与其对HLA-DR的抑制作用有关。     

普拉洛芬联合rhEGF滴眼液治疗白内障术后干眼症的效果

目的探讨普拉洛芬联合重组人表皮生长因子(rhEGF)滴眼液治疗白内障术后干眼症的临床效果。方法将白内障术后发生干眼症的患者94例随机分为普拉洛芬组和联合治疗组,每组47例。普拉洛芬组采用普拉洛芬滴眼液治疗,联合治疗组采用普拉洛芬滴眼液联合rhEGF滴眼液治疗。比较两组患者临床疗效、干眼症状评分、泪膜破裂时间(BUT)、泪液分泌长度、角膜荧光素染色(FL)评分和泪液炎性因子水平。结果普拉洛芬组治疗总有效率为83.12%,显著低于联合治疗组的97.47%(P<0.05)。治疗后,两组干眼症状评分均降低,且联合治疗组显著低于普拉洛芬组(P<0.05)。治疗后,联合治疗组BUT、泪液分泌长度显著长于普拉洛芬组,FL评分显著低于普拉洛芬组(P<0.05)。治疗后,两组泪液IL-1β、IL-6、TNF-α水平均较治疗前显著下降,且联合治疗组低于普拉洛芬组(P<0.05)。结论普拉洛芬滴眼液联合rhEGF滴眼液可促进白内障术后干眼症泪膜修复、减轻炎症反应,改善干眼症状。